High-Dose-Rate Intracavitary Brachytherapy Boost for Early T Stage Nasopharyngeal Carcinoma{PRIVATE}
| Autor: | To-Wai Leung, Stewart Y. Tung, W.K. Sze, Collin M.M. Lui, Victy Y.W. Wong |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research medicine.medical_treatment Brachytherapy Disease-Free Survival Dose escalation Humans Medicine Radiology Nuclear Medicine and imaging Survival rate Neoplasm Staging Radiation business.industry Carcinoma Intracavitary brachytherapy Nasopharyngeal Neoplasms Radiotherapy Dosage Middle Aged medicine.disease Survival Rate Oncology Nasopharyngeal carcinoma Case-Control Studies Total dose T-stage Female Neoplasm Recurrence Local Dose rate business Nuclear medicine |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 70:361-367 |
| ISSN: | 0360-3016 |
| Popis: | Purpose To investigate any possible therapeutic gain from dose escalation with brachytherapy for early T stage nasopharyngeal carcinoma (NPC). Methods and Materials One hundred forty-five patients with T1–2b N0–3 NPC were boosted with high-dose-rate intracavitary brachytherapy after completion of two-dimensional external radiotherapy (ERT) during the period from 1999 to 2003. To compare the efficacy of brachytherapy boost, another 142 patients with T1–2b N0–3 disease who were treated with ERT alone during 1994 to 1999 were evaluated. All patients were treated with ERT to a total dose of 66 Gy in 6.5 weeks. The brachytherapy boost group was given 10–12 Gy in 2 weekly fractions. Results Dose escalation beyond 66 Gy with brachytherapy boost was shown to improve local control and survival. The 5-year actuarial local failure-free survival, regional failure-free survival, distant metastasis-free survival, progression-free survival, cancer-specific survival, and overall survival rates for the brachytherapy group and the control group were 95.8% and 88.3% ( p = 0.020), 96% and 94.6% ( p = 0.40), 95% and 83.2% ( p = 0.0045), 89.2% and 74.8% ( p = 0.0021), 94.5% and 83.4% ( p = 0.0058), and 91.1% and 79.6% ( p = 0.0062), respectively. The 5-year major-complication-free survival rate was 89.5% for the brachytherapy group and 85.6% for the control group ( p = 0.23). Conclusions For patients who are treated with two-dimensional treatment techniques, dose escalation with brachytherapy boost improves local control and overall survival of patients with T1–T2a and possibly non-bulky T2b disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|